Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
New Data Supports Clinical Rationale for Bertilimumab in Ulcerative Colitis Phase II Trial to Focus on Moderate to Severe UC Patients with...
iCo Therapeutics Grants Options to a Director PR Newswire VANCOUVER, Sept. 5, 2013 VANCOUVER, Sept. 5, 2013 /PRNewswire/ - iCo Therapeutics Inc...
iCo Therapeutics to Present at the Rodman & Renshaw 2013 Annual Global Investment Conference PR Newswire VANCOUVER, Sept. 4, 2013 VANCOUVER...
iCo Therapeutics Announces Second Quarter 2013 Financial Results PR Newswire VANCOUVER, Aug. 26, 2013 VANCOUVER, Aug. 26, 2013 /PRNewswire/ - iCo...
iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular...
Immune Pharmaceuticals CEO to Chair BIO International Panel "Can Israel Become the Next Biotech Startup Nation?" PR...
Isaac Kobrin, M.D. Joins IMMUNE Pharmaceuticals' Board of Directors -- Former Chief Medical Officer at Actelion Pharmaceuticals -- Leadership...
iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema PR Newswire VANCOUVER, Sept. 26, 2011 VANCOUVER, Sept. 26...
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer IMMUNE prepares for phase II clinical trials in Crohn's...
SCOTT DEPOT, W.Va., Sept. 29 /PRNewswire-FirstCall/ -- International Coal Group, Inc. (NYSE:ICO) today announced it has entered into an...
ASHLAND, Ky., Nov. 21 /PRNewswire/ -- International Coal Group, Inc. today announced that its common stock had been admitted for trading on the...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지